EcoDrugPlus

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSEEEG00000017694
Gene Symbol: KCNN4
4 Cross references
191 Possible Orthologues:

Potassium Channel, Subfamily K, Member 2b

Ensembl ID : ENSEEEG00000018080
Gene Symbol: KCNK2B
2 Cross references
214 Possible Orthologues:

Potassium Channel, Subfamily K, Member 9

Ensembl ID : ENSEEEG00000020990
Gene Symbol: KCNK9
4 Cross references
219 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSEEEG00000007443
Gene Symbol: KCNJ11
4 Cross references
189 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSEEEG00000021017
Gene Symbol: KCNJ2
2 Cross references
197 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2a

Ensembl ID : ENSEEEG00000010621
Gene Symbol: KCNJ2A
4 Cross references
202 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSEEEG00000012277
Gene Symbol: KCNJ3
4 Cross references
218 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSEEEG00000019764
Gene Symbol: KCNJ3
4 Cross references
152 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSEEEG00000023179
Gene Symbol: KCNJ5
1 Cross references
209 Possible Orthologues:

Potassium Large Conductance Calcium-Activated Channel, Subfamily M, Alpha Member 1a

Ensembl ID : ENSEEEG00000006264
Gene Symbol: KCNMA1A
4 Cross references
177 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSEEEG00000020915
Gene Symbol: KCNA5
4 Cross references
170 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSEEEG00000013250
Gene Symbol: KCND3
4 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).